ASX flat, CSL seals $16.4bn Vifor deal
ASX closes flat on real estate gains and heavy retail losses, CSL to buy Vifor for $16.4bn, Mesoblast tumbles 17.4 per cent, Woolies dives on profit warning and Polynovo soars 15.4 per cent.
Csl
Australia’s $17bn game-changing jab deal
Australia’s pharmaceutical giant, CSL, which locally produced the AstraZeneca vaccine, has its eyes on a bigger prize to produce a bigger, more profitable jab.
CSL poised for $16.7bn Vifor takeover
CSL, the nation’s largest biotechnology company, is expected to finalise a $US12bn deal to acquire Swiss firm Vifor Pharma as early as Tuesday.
Investors back pending CSL-Vifor deal
Shares in CSL are set to fly out the door should it raise equity to buy Vifor Pharma, with Australia’s largest healthcare company confirming it is talks with the Swiss target.
ASX rises 0.3%; Wyloo trumps BHP for Noront
ASX closes higher on property and energy gains, Wyloo Metals trumps BHP offer for Noront, Charter Hall surges on guidance and ANZ arm extends Cashrewards takeover.
Mammoth CSL acquisition could come early
Bank of America’s Australian offices are said to be a hive of activity right now, suggesting a CSL deal may land sooner than expected.
ASX follows northern markets lower
The ASX followed the negative lead of US and European markets, with Afterpay and CSL proving major drags.
Centerview role in Vifor talks
Swiss healthcare company Vifor Pharma is understood to be working with adviser Centerview Partners as part of a plan to sell itself to CSL.
Analysts query CSL’s play for Vifor Pharma
Why CSL wants to acquire Swiss medical company Vifor Pharma is not ‘immediately apparent’, according to equities analysts at investment bank Macquarie.
ASX rallies; TPG tanks; CSL down on Vifor talks
ASX 200 has closed up 0.2 per cent, following a 20-day low in midday trade, as heavyweight energy and financial stocks rose.
CSL makes $10bn play for Vifor Pharma
Australian healthcare giant CSL is believed to be in exclusive talks to buy a European company in a deal that could be worth as much as $10bn.
ASX closes down 0.15%, Afterpay dives
ASX closes down 0.15 per cent, CSL eyeing $10bn firm, Afterpay dives after delayed Square vote, API soars on Woolies bid and Coles faces court action.
CSL’s supporting role in $95m biotech incubator
CSL will support, but not lead, a $95m joint incubator project that could ‘put Australia on the map’ for biotech developments.
ASX closes up 0.6% despite Westpac slump
Stocks closed up 0.6 per cent, driven by CSL, CBA, Wesfarmers and Telstra. AusNet backs $10.2bn Brookfield bid. Investors dump Westpac, despite $3.5bn buy back.
CSL warms to heat-tolerant mRNA vaccine
Australia’s biggest health company is adopting new technology deployed against Covid-19 in its next generation of flu vaccines.
End vaccine blame game: CSL
CSL chief Paul Perreault has warned that the politicisation of Covid-19 is fuelling vaccination hesitancy as the global pharma giant makes jabs mandatory.
Vaccines giant mandates staff jabs
An Aussie pharmaceutical giant in the thick of the Covid-19 battle has told all staff “no jab, no job” and defended one vaccine as unfairly panned.
CSL mandates Covid-19 vaccines
Biotech giant CSL’s boss Paul Perreault says the politicisation of Covid-19 is not helpful and that vaccination is the only way to return the world to normality.
Vaccination not the only sharemarket challenge
Bond yields rising, stimulus programs running out – the risks are out there for sharemarket investors.
ASX drops 1.5%, CSL, BHP, Fortescue hit
Stocks finish 1.5 per cent lower, hurt by biotech giant CSL, BHP and Fortescue Metals. Retail sales fall 1.7 per cent. Oil prices hit their highest level since 2018 and iron ore jumped.
Original URL: https://www.theaustralian.com.au/topics/csl/page/8